Specifica

What Specifica does

Specifica, Inc. is a privately held antibody engineering company founded in 2016 and headquartered in Santa Fe, New Mexico, operating as a subsidiary of Q2 Solutions (part of IQVIA). The company builds and transfers Generation 3 in vitro antibody libraries using phage and yeast display, combined with next-generation sequencing quality control, and complements these libraries with AbXtract, a cloud-based bioinformatics module (exclusively embedded in OpenEye's Orion Antibody Discovery Suite) that uses proprietary ML methods to cluster antibody sequences and identify leads from NGS outputs. Libraries are delivered in Fab, scFv, and VHH formats, and Specifica reports that over 80% of output antibodies show no measurable biophysical liabilities, with 60% below 10 nM affinity and 20% subnanomolar.

Specifica monetizes primarily through full platform transfer agreements with global pharmaceutical companies — delivering exclusive libraries, vectors, protocols, and training under multi-year contracts with no downstream royalties — supplemented by in-house antibody discovery services, custom library design, and AI Antibody Data Packages sold to AI/ML model developers. The go-to-market is enterprise field sales targeting pharma R&D and discovery teams; named customers include Sanofi, Servier/Symphogen, Bayer, UCB, AstraZeneca, Incyte, and Scholar Rock. Marketing relies heavily on peer-reviewed publications (Nature Communications, mAbs), conference presence (PEGS, Festival of Biologics), webinars, and an antibody engineering masterclass.

The business is differentiated by patented library construction methods, donor-set exclusivity for each partner, and validated developability metrics; however, scale remains modest (11-50 employees) and no revenue or external funding figures have been disclosed.

Name

Specifica

Legal name

Specifica Inc.

Website

https://specifica.bio

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Specifica is a Santa Fe-based, IQVIA-affiliated antibody engineering company that designs and transfers proprietary Generation 3 in vitro antibody libraries, paired with cloud-based AbXtract bioinformatics, to global pharmaceutical and biotechnology partners for therapeutic discovery.

Ownership category

akta.pro rank

Product category

Antibody Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Antibody library design
• Antibody discovery services
• Phage display technology
• Biologics platform transfer
• Therapeutic antibody engineering

Headquarters

HQ city

Santa Fe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Transfer Agreements: Exclusive transfer of Generation 3 antibody libraries, vectors, protocols, and training to pharmaceutical partners. Each library is created from unique donor sets not used for any other library.
2. Antibody Discovery Services: In-house antibody discovery campaigns using Specifica's Generation 3 Platform for partners who need additional support.
3. Custom Library Design: Collaborative creation of custom antibody display libraries with optimized essential elements according to partner specifications.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Specifica designs and delivers Generation 3 in vitro antibody display libraries in Fab, scFv, and VHH formats using phage and yeast display technologies, transferring them to pharmaceutical and biotechnology partners as exclusive assets with vectors, protocols, and training. The company also runs in-house antibody discovery campaigns, provides custom library design services, and offers AbXtract, a cloud-based NGS bioinformatics tool integrated with OpenEye's Orion platform, along with AI Antibody Data Packages for training computational antibody discovery models.

Product overview

Specifica offers a unified antibody discovery ecosystem centered on its Generation 3 Antibody Library Platform as the core technology. The platform combines patented Generation 3 libraries (available in Fab, scFv, and VHH formats) with AbXtract, a cloud-based NGS bioinformatics module exclusively available through the OpenEye Orion platform. Customers access the platform through platform transfer agreements (full technology transfer with exclusive libraries, vectors, protocols, and training) or discovery services (Specifica conducts campaigns on their behalf). AI Antibody Data Packages provide supplementary data for AI/ML training. The ecosystem also includes VHH/single-domain libraries, R&D services, and reagents.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 60% of antibodies from Generation 3 libraries have affinities below 10nM; 20% subnanomolar; best affinity 13 pM
• +3 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered major, core and strategic.

• Servier / SymphogenmajorStrategic or Co-development Partner · 17 March 2023Platform transfer agreement providing Generation 3 antibody libraries, optimization tools, and computational tools to Symphogen (Servier's antibody center of excellence) for integration into their discovery programs in oncology, neuroscience, and immuno-inflammation.
• SanofimajorStrategic or Co-development Partner · 2 June 2022Comprehensive technology transfer of Specifica's patented Generation 3 Antibody Discovery Platform including Gen 3 libraries, antibody optimization solutions, and integrated discovery tools.
• OpenEye ScientificcoreTechnology or Integration · 2 December 2021Joint development partnership to launch Orion Antibody Discovery Suite incorporating Specifica's AbXtract module. OpenEye's cloud-native Orion platform combined with Specifica's bioinformatics tools for antibody discovery analysis.
• IncytestrategicStrategic or Co-development Partner · 1 January 2021Collaborative development resulting in published research on single donor in vitro library builds and simultaneous affinity maturation with developability enhancement methods.
• UCBmajorStrategic or Co-development Partner · 1 December 2020Delivery of exclusive antibody library platform to enhance UCB's therapeutic antibody discovery capabilities, providing reliable and rapid source of therapeutic antibody molecules.
• Scholar RockmajorStrategic or Co-development Partner · 5 August 2020Collaborative design and creation of exclusive antibody display library based on Specifica's Generation 3 platform for therapeutic biologic discovery targeting serious diseases.
• BayermajorStrategic or Co-development Partner · 12 May 2020Transfer of Generation 3 antibody library suite to Bayer under agreement enabling development of antibody-based therapeutics, following in-house testing by Bayer.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adimab: Adimab operates one of the leading proprietary antibody discovery platforms (yeast display-based) used by major pharma for therapeutic antibody leads, directly competing with Specifica's Generation 3 library offering.
• AbCellera Biologics: AbCellera runs a single-cell antibody discovery platform with deep pharma partnerships (including Eli Lilly) and competes directly for antibody discovery platform transfer and partnership engagements.
• Ligand Pharmaceuticals (OmniAb): Ligand's OmniAb business offers transgenic animal and in vitro antibody discovery platforms licensed to pharma and biotech — a directly comparable business model to Specifica's platform transfer approach.
• Trianni: Trianni provides transgenic human antibody mouse platforms and discovery services, serving the same pharma/biotech therapeutic antibody discovery customer base as Specifica.
• Yumab: Yumab offers proprietary antibody library and phage/yeast display-based discovery services to pharma partners, overlapping with Specifica's library and discovery service offerings.

Broad incumbents

• Charles River Laboratories (Distributed Bio): Charles River acquired Distributed Bio and integrates antibody library and discovery capabilities into a broader CRO services portfolio, competing for the same pharma discovery budgets as Specifica.
• GenScript ProBio: GenScript offers antibody discovery services, library construction, and reagents across a broad biologics services portfolio, including custom antibody library offerings overlapping with Specifica's value proposition.
• Bio-Rad Laboratories: Bio-Rad's Life Science segment provides antibody reagents, phage display libraries, and related tools used in antibody discovery and validation, addressing adjacent customer needs to Specifica's offerings.

Emerging players

• Ablexis (AlivaMab Biologics): Ablexis / AlivaMab provides a transgenic human antibody mouse platform for therapeutic discovery, representing an alternative in vivo approach that competes with Specifica's in vitro library platform for the same pharma partnerships.
• Atreca: Atreca applies immune repertoire sequencing and AI to antibody discovery, overlapping with Specifica's NGS-driven selection workflow and target customer base of pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/specificainc
• LinkedInlinkedin.com/company/specifica-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Specifica